BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 210 participants.
Also called NCT07755904
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 210 participants
- Sponsor
- Braveheart Bio, Inc.
- Registry
-
NCT07755904 -
2026-526007-30-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT07755904. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-02 (actual); primary completion 2028-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Acronym
- LIONHEART-HCM
- Condition
- Cardiomyopathy, Hypertrophic Obstructive
- Intervention (Drug)
- BHB-1893
- Intervention (Drug)
- Metoprolol
- Lead sponsor
- Braveheart Bio, Inc.
Record details
- Record id
cardio:ct-nct07755904- Content hash
1f419ac343ecd0a96e59d201f32aa6b26280018b159831628566657cbcb789f4